Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.61 |
| ▸ | CTSD | P07339 | 9/20 | 0.58 |
| ▸ | BACE1 | P56817 | 11/20 | 0.56 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4214871 | 1.00 | BCHE (0.61) | BCHECTSDBACE1DNM1MEN1 | |
| Hydrochloric Acid SCHEMBL5348922 | 0.99 | BCHE (0.60) | BCHECTSDBACE1DNM1MEN1 | |
| Hydrochloric Acid SCHEMBL6110582 | 0.99 | BCHE (0.60) | BCHECTSDBACE1DNM1MEN1 | |
| SCHEMBL3352016 | 0.91 | BCHE (0.51) | BCHECTSDBACE1MEN1KMT2A | |
| SCHEMBL5205801 | 0.91 | LMNA (0.54) | BCHECTSDBACE1DNM1 | |
| SCHEMBL3876015 | 0.91 | LMNA (0.54) | BCHECTSDBACE1DNM1 | |
| Hydrochloric Acid SCHEMBL5220538 | 0.90 | LMNA (0.53) | BCHECTSDBACE1DNM1 | |
| SCHEMBL4039356 | 0.89 | KDM4E (0.50) | BCHECTSDBACE1MEN1KMT2A | |
| SCHEMBL3349956 | 0.88 | BACE1 (0.57) | CTSDBACE1 | |
| SCHEMBL13409422 | 0.88 | BACE1 (0.57) | CTSDBACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | claimed |
| JP-2004502669-A | — | — | 2004-01-29 | — | — | JP | claimed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PHARMACIA & UPJOHN COMPANY | 2002-09-12 | — | — | US | claimed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | claimed |
| WO-2017066742-A1 | BACE-2 INHIBITORY COMPOUNDS AND RELATED METHODS OF USE | JORTAN PHARMACEUTICALS INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| EP-2611441-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-07-10 | — | — | EP | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| WO-2012028563-A1 | BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-08 | — | — | WO | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-20120053200-A1 | BACE 2 INHIBITORS | HOFFMANN-LA ROCHE INC. | 2012-03-01 | — | — | US | disclosed |
| US-7727997-B2 | N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives | ELAN PHARMACEUTICALS, INC. (US) | 2010-06-01 | — | — | US | disclosed |
| WO-2006040148-A1 | TRICYCLIC INDOLE DERIVATIVES FOR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-04-20 | — | — | WO | disclosed |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | US | disclosed |
| EP-1620438-A1 | TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005058915-A1 | TRICYCLIC INDOLE HYDROXYETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE | GLAXO GROUP LIMITED (GB) | 2005-06-30 | — | — | WO | disclosed |
| WO-2005014517-A2 | NOVEL DIBENZO[B,F]OXEPINE-10-CARBOXAMIDES AND PHARMACEUTICAL USES THEREOF | NOVARTIS AG (CH) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004094430-A1 | TRICYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER’S DISEASE | GLAXO GROUP LIMITED (GB) | 2004-11-04 | — | — | WO | disclosed |
| EP-1353898-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002002512-A2 | COMPOUNDS TO TREAT ALZHEIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229302-A1 | Tricyclic indole derivatives and their use in the treatment of alzheimer's disease | BACE2, BACE1, PSEN2 | BCHE 24/4885CTSD 264/4885BACE1 2/4885 |
| US-20020128255-A1 | Compounds to treat alzheimer's disease | PSEN2, PSEN1, APP | BCHE 12/4885CTSD 2080/4885BACE1 4/4885 |
| US-20060025459-A1 | Hydroxyethylamine derivatives for the treatment of alzheimer's disease | BACE2, PSEN2, BACE1 | BCHE 11/4885CTSD 384/4885BACE1 3/4885 |
| US-20120053200-A1 | BACE 2 INHIBITORS | BACE2, BACE1, PSEN2 | BCHE 22/4885CTSD 138/4885BACE1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.